HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd; U3-1402) in previously treated metastatic EGFR-mutated NSCLC Meeting Abstract
| Authors: | Janne, P.; Johnson, M.; Goto, Y.; Yang, J. C.; Karam, S.; Chen, S.; Qiu, Y.; Yu, H.; Yu, C. |
| Abstract Title: | HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd; U3-1402) in previously treated metastatic EGFR-mutated NSCLC |
| Meeting Title: | 2020 World Conference on Lung Cancer |
| Keywords: | nsclc; her3; antibody drug conjugate |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 16 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 28-31 |
| Meeting Location: | Singapore |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-03-01 |
| Start Page: | S236 |
| Language: | English |
| ACCESSION: | WOS:000631349600312 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2021.01.325 |
| Notes: | Meeting Abstract: P01.01 -- Due to Covid-19 pandemic, the conference was held virtually -- Source: Wos |
